Mucosal (e.g., Nasal, Etc.) Patents (Class 424/434)
  • Patent number: 10702509
    Abstract: Compositions and methods for the treatment and control of various conditions in an animal which comprises administering to said animal an effective amount of a immediate release composition of about 0.5% to 50% wt/wt of active ingredient together with excipients to a total of about 100%, wherein said composition dissolves in a relatively short period of time, e.g., 75 seconds or less, 5 seconds or less, or 3 seconds or less, upon administration to said animal.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: July 7, 2020
    Assignee: NewMarket Pharmaceuticals LLC
    Inventors: David Rock, Mark Ridall
  • Patent number: 10695335
    Abstract: Provided is a patch preparation that has improved adhesion to an adherend so as to enable a drug, especially, a systemically active drug to be stably and continuously administered over an extended period. The patch preparation has a layered structure comprising a patch layer including an adhesive plaster containing a drug and a patch support, and a cover layer in this order from a side attached to a skin. In the patch preparation, a buffer material is disposed between the patch support of the patch layer and the cover layer, the cover layer has a size covering an area beyond peripheral edges of the patch layer, and a shielding film is further disposed between the cover layer and the buffer material.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: June 30, 2020
    Assignee: Teikoku Seiyaku Co., Ltd.
    Inventor: Satoshi Kawakami
  • Patent number: 10688069
    Abstract: A topical composition that includes L-arginine that is used as a sports health composition. The composition can further include forskolin. Disclosed is a method of using the topical composition.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: June 23, 2020
    Assignee: REV Pharmaceuticals LLC
    Inventors: Beth Anne-Szkudlarek Brown, Anthony Lemus, Marnie L. Peterson
  • Patent number: 10624793
    Abstract: An article 1 comprises a hydrophilic foam layer 3; a reservoir cover 5 in contact with a first main surface of the hydrophilic foam layer 3, the reservoir cover 5 enclosing a reservoir cavity 7 together with the first main surface of the hydrophilic foam layer 3, the reservoir cavity 7 being for containing a fluid; and a hydrophobic foam layer 9 formed over the first main surface of the hydrophilic foam layer 3 and the reservoir cover 5. Fluid can be dispensed from the reservoir cavity 7 through a lower surface of the hydrophilic foam layer 3 by pressing on the hydrophobic foam layer 9 so that the reservoir cover 5 is compressed.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: April 21, 2020
    Assignee: DENTMED LIMITED
    Inventor: Ian Malcolm Vickery
  • Patent number: 10625242
    Abstract: A solid substrate for the extraction, stabilization, and storage of proteins is provided. The substrate includes: a polysaccharide, such as melezitose under a substantially dry state. The substrate is configured to extract proteins from a sample and stabilize the extracted proteins in a dry format under ambient conditions for a prolonged period of time. Methods for collecting and recovering the proteins stored in the dry solid substrate are also described.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: April 21, 2020
    Assignee: General Electric Company
    Inventors: Ernest William Kovacs, Frank John Mondello, Erik Leeming Kvam, Bing Li
  • Patent number: 10617143
    Abstract: A smokeless tobacco product is provided that includes a tobacco material in the form of a tobacco extract, a particulate tobacco material, or a combination thereof. In some embodiments, the smokeless tobacco product is substantially translucent. Methods for making and using the smokeless tobacco product are also provided. The smokeless tobacco product can include isomalt, maltitol syrup, particulate tobacco, and a translucent tobacco extract prepared by ultrafiltration.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: April 14, 2020
    Assignee: R.J. Reynolds Tobacco Company
    Inventor: Darrell Eugene Holton, Jr.
  • Patent number: 10596187
    Abstract: Provided herein are compositions, for example: oral rehydration compositions, beverages, food items, methods and uses, which utilise resistant starch to prevent or treat dehydration, including dehydration which is caused by diarrhoea. Beverages, food items and oral rehydration solutions including a resistant starch, which are suitable for aiding in the maintenance and restoration of hydration levels in individuals undertaking physical activities, including sports, are also disclosed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: March 24, 2020
    Assignees: Yale University, Flinders University of South Australia, Balakrishnan Siddartha Ramakrishna
    Inventors: Balakrishnan Siddartha Ramakrishna, Graeme Paul Young, Ian Lewis Brown, Henry Joseph Binder
  • Patent number: 10590403
    Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acinetobacter lysin polypeptides.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: March 17, 2020
    Assignee: The Rockefeller University
    Inventors: Vincent Fischetti, Raymond Schuch, Rolf Lood, Benjamin Winer
  • Patent number: 10583081
    Abstract: A kit that is made of an apparatus comprising a bottle and a nozzle sprayer, and a pharmaceutical formulation comprising dyclonine HCL, triamcinolone, dicyclomine, and dental powder. A method for treating mouth ulcers comprising administering to a patient a formulation comprising dyclonine HCL, triamcinolone, dicyclomine, and dental powder to an affected area.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: March 10, 2020
    Inventor: Richard A. Myers
  • Patent number: 10548819
    Abstract: The invention features a composition which can or is to be used in a dental retraction, the composition comprising liquid a liquid and a layer type 1:1 silicate mineral and a layer type 2:1 silicate mineral in a ratio from about 50/50 to 5/95 wt.-% with respect to each other. The invention also relates to a container containing the dental retraction composition and to a kit comprising parts A and B, wherein part A comprises the dental retraction composition and part B comprises at least one accessory selected from the group of applier, dental impression material, retraction cap(s), a container for storing and dispensing the composition and combinations thereof. The invention further features a process of dispensing a dental retraction composition, the process comprising the steps: providing a dental retraction composition contained in a container, placing the container in an applier, and using the applier for dispensing the dental retraction composition out of the container.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: February 4, 2020
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Andreas R. Maurer, Christoph Schulte, Rüdiger Hampe, Johannes M. Leykauff, Helmut Pauser
  • Patent number: 10532033
    Abstract: The invention relates to a transdermal therapeutic system on the basis of polysiloxane which contains microreservoirs filled with an active substance and one ambiphilic solvent.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: January 14, 2020
    Assignee: LTS LOHMANN Therapie-Systeme AG
    Inventor: Walter Müller
  • Patent number: 10507216
    Abstract: A method for olfactory improvement with saccharide. The saccharide is a chitin-based material, proteoglycan, glycosaminoglycan, amino monosaccharide, N-acylated amino monosaccharide or a combination thereof.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: December 17, 2019
    Inventor: Tsung-Wei Huang
  • Patent number: 10493071
    Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.
    Type: Grant
    Filed: May 30, 2017
    Date of Patent: December 3, 2019
    Assignee: HELPERBY THERAPEUTICS LIMITED
    Inventors: Petra Helga Beck, Marc Barry Brown, David Edward Clark, Anthony Coates, Hazel Joan Dyke, Yanmin Hu, Derek John Londesbrough, Keith Mills, Thomas David Pallin, Gary Patrick Reid, Gerlinda Stoddart
  • Patent number: 10485817
    Abstract: The present embodiments relate to the use of dextran sulfate having an average molecular weight below 10 000 Da for inducing angiogenesis in a subject and for increasing blood flow in a subject suffering from ischemia.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: November 26, 2019
    Assignee: TX MEDIC AB
    Inventors: Anders Waas, Lars Bruce, Adam Bruce
  • Patent number: 10471021
    Abstract: The invention relates to a transdermal therapeutic system (TTS), which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system includes a back layer and an active substance-containing layer that contains at least one peptide and a carrier substance, preferably as a textile web material.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 12, 2019
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Horstmann, Gerd Hoffmann, Sandra Wiedersberg
  • Patent number: 10456386
    Abstract: The present disclosure relates to a pharmaceutical composition comprising as active substance betahistine or a pharmaceutically acceptable salt thereof, for use in the treatment of otological or neurological disorders in a human subject by intranasal application.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: October 29, 2019
    Assignee: OTOLANUM AG
    Inventors: Christopher John Wraight, Thomas Meyer
  • Patent number: 10407423
    Abstract: It relates to the compounds of formula (I), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, wherein A, R1, R2, and R3 are as defined herein, which are inhibitors of one or more DNMTs selected from the group consisting of DNMT1, DNMT3A and DNMT3B. It also relates to pharmaceutical or veterinary compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of cancer, fibrosis and/or immunomodulation.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: September 10, 2019
    Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA
    Inventors: Xabier Aguirre Ena, Julen Oyarzabal Santamarina, Felipe Prósper Cardoso, Maria Obdulia Rabal Gracia, Edurne San José Enériz, Juan Antonio Sánchez Arias
  • Patent number: 10391087
    Abstract: The present invention is effective for the treatment and relief of cough produced by posterior nasal secretion, through the use of the combination of Oximetazoline and Ipratropium. The active agents enunciated in the combination of the present invention have been used and marketed separately with different uses to those of the present invention. The oxymetazoline to eliminate nasal secretion and congestion (obstruction), and ipratropium bromide is marketed for the purpose of dilating the bronchial tubes in asthmatic patients with chronic obstructive pulmonary disease, although experimentally it has also been used to decrease nasal secretion. Both active agents, together or separately have not been used so far as antitussives intranasally. The cough produced by the posterior nasal secretion, is the most frequent cause of cough in the human being of any age, the present invention is effective for the treatment and relief of said symptom.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: August 27, 2019
    Inventor: Pablo Cortes Borrego
  • Patent number: 10370402
    Abstract: The invention relates to a novel crystallization process for preparing fluticasone propionate as crystalline form 1 polymorph with controlled particle size and suitable for micronization. Said process comprises the step of dissolving fluticasone propionate in acetone or in a mixture of acetone and water and then adding this solution to water or to a mixture of water 10 and acetone, thereby causing fluticasone propionate to crystallize out of the solution as crystalline form.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: August 6, 2019
    Assignee: Pfizer Limited
    Inventors: Martyn David Ticehurst, Ivan Marziano, Eleftherios Kougoulos
  • Patent number: 10272125
    Abstract: Transdermal delivery devices for the delivery of cannabidiol (CBD) and related moieties are shown and described. In a reservoir-patch design, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In using CBD as a pure compound or as one to combine with other moieties, the invention is able to control delivery better than the prior art.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: April 30, 2019
    Assignee: Life Tech Global, LLC
    Inventor: Ludwig Weimann
  • Patent number: 10265309
    Abstract: Sublingual formulations containing an opioid, preferably, fentanyl or a pharmaceutically acceptable salt or ester thereof, naloxone or a pharmaceutically acceptable salt or ester thereof, and a terpene; as well as methods of treating pain by administering the formulations of the invention to a patient in need thereof.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: April 23, 2019
    Assignee: INSYS DEVELOPMENT COMPANY, INC.
    Inventors: Ning Shan, Rajesh R. Wakaskar, Edwin A. Baldwin, Andrew B. Schlinkert, Min Wu, Ningxin Yan
  • Patent number: 10258681
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: April 16, 2019
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Patent number: 10245034
    Abstract: Tissue adhesions using surgical adjuncts and medicants are provided. In general, an implantable adjunct can have one or more medicants releasably retained therein that are configured to induce tissue adhesions. The adjunct can be configured to be applied to lung tissue in conjunction with surgical staples using a surgical stapler. Pleurodesis can be encouraged through delivery of the adjunct to the lung tissue.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: April 2, 2019
    Assignee: Ethicon LLC
    Inventors: Frederick E. Shelton, IV, Jason L. Harris, Michael J. Vendely, Charles J. Scheib
  • Patent number: 10143655
    Abstract: Methods are provided for promoting the adsorption of an active agent to microparticles by modifying the structural properties of the active agent in order to facilitate favorable association to the microparticle.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: December 4, 2018
    Assignee: MannKind Corporation
    Inventors: Mark Hokenson, Keith A. Oberg
  • Patent number: 10130581
    Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: November 20, 2018
    Assignee: MannKind Corporation
    Inventors: Bryan R. Wilson, Marshall Grant
  • Patent number: 10098379
    Abstract: A device for simulating a chemosenzation of smoking includes an outer layer, a porous medium and a chemesthetic agent. The porous medium is disposed within the outer layer. The chemesthetic agent is disposed within the porous medium and activates a TRP channel.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 16, 2018
    Assignee: Sentiens, LLC
    Inventors: Reid von Borstel, Dennis Tan, John Siverling, Inna S. Timokhina
  • Patent number: 10045984
    Abstract: The present invention provides a composition comprising zinc and trimethoprim, particularly in a weight ration of about 1:3 to about 1:7, as well as a sustained- or prolonged-release preparation which comprises trimethoprim and zinc and a biodegradable polymer providing a clinically useful composition which has prolonged release over a long period of time.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: August 14, 2018
    Inventor: Magdi El-Habbal
  • Patent number: 10016534
    Abstract: The present invention relates to protein biocoacervates and biomaterials vessel graft systems used in cardiovascular applications and other medical applications, the components utilized in the vessel graft systems and the methods of making and using such systems. More specifically the present invention relates to protein biocoacervates and biomaterials vessel graft systems used in various medical applications and/or the devices used in such vessel graft systems including, but not limited to, vessel grafts as drug delivery devices for the controlled release of pharmacologically active agents, tubular grafts, vascular grafts, protein biomaterial sutures and biomeshes, protein biomaterial adhesives and glues, and other biocompatible biocoacervate or biomaterial devices used in the vessel graft systems of the present invention.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: July 10, 2018
    Assignee: Gel-Del Technologies, Inc.
    Inventor: David B. Masters
  • Patent number: 9999243
    Abstract: An exhausted-tobacco lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix, exhausted-tobacco fiber, and one or more additives (e.g. nicotine or a derivative thereof) dispersed in the soluble-fiber matrix. In some cases, an exhausted-tobacco lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in exhausted-tobacco lozenge provided herein can include maltodextrin. The exhausted-tobacco lozenge is adapted to release the nicotine or a derivative thereof from the body when the body is received within the oral cavity of an adult tobacco consumer and exposed to saliva. A method of making exhausted-tobacco lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, exhausted-tobacco fiber, one or more additives (e.g., nicotine), and less than 15 weight percent water while maintaining a mixture temperature of less than 150° C.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: June 19, 2018
    Assignee: ALTRIA CLIENT SERVICES LLC
    Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke
  • Patent number: 9993444
    Abstract: The chronic use of p-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a p-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. The invention further encompasses pharmaceutical compositions comprising the p-adrenergic inverse agonist and the additional compound.
    Type: Grant
    Filed: January 9, 2012
    Date of Patent: June 12, 2018
    Assignee: INVION, INC.
    Inventors: Richard A. Bond, Mitchell Glass
  • Patent number: 9981092
    Abstract: The invention relates to a method for the manufacture of a pressurized Metered Dose Inhaler (pMDI) and components for use in said method, in particular, a pMDI compatible tablet (i.e. one that is able to be dispersed or disintegrates within a liquid phase, such as a propellant, used in a pMDI formulation) which contains at least one active pharmaceutical ingredient (API) and, optionally, one or more excipients.
    Type: Grant
    Filed: February 12, 2015
    Date of Patent: May 29, 2018
    Assignee: CARDIFF SCINTIGRAPHICS LIMITED
    Inventors: Glyn Taylor, Simon Warren, Cuong Tran
  • Patent number: 9937232
    Abstract: The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 10, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERISITE DE ROUEN, UNIVERSITE DE REIMS, CENTRE HOSPITALIER UNIVERSITE DE ROUEN
    Inventors: Ebba Brakenhielm, Sébastien Banquet, Florence Edwards-Levy, Christian Thuillez
  • Patent number: 9924739
    Abstract: A portioned moist tobacco product with a super-hydrated membrane coating and method of manufacturing is disclosed. The super-hydrated membrane coating is formed by ionic cross-linking using two polymers. The soluble component of the super-hydrated membrane coating dissolves upon placement in the mouth, while the insoluble component maintains the tobacco within the coating for the duration of the use of the product. The moist tobacco product is soft and flexible so as to fit comfortably in an oral cavity when placed therein.
    Type: Grant
    Filed: April 21, 2015
    Date of Patent: March 27, 2018
    Assignee: Philip Morris USA Inc.
    Inventors: Munmaya K. Mishra, William R. Sweeney, Shensheng Liu, Kenneth A. Newman, Steven J. Hovjacky
  • Patent number: 9901587
    Abstract: The described invention provides a topical bioadhesive film-forming pharmaceutical composition formulated for application directly to skin or to a substrate. The composition includes a therapeutic amount of an active agent; and one or more excipients selected from the group consisting of a non-cellulosic polymer or copolymer, a film forming agent, a plasticizer, a permeation enhancer, an antioxidant, a preservative, a solubilizer, a phase transfer catalyst, a viscosity modifier, a vitamin, a mineral nutrient, a solvent, a colorant and a fragrance. It further provides a delivery system comprising the composition and a means for administering the composition. It also describes uses of the delivery system in the manufacture of a medicament for treating a skin condition, disease or disorder, and a method for treating a skin condition, disease or disorder with the composition. The composition is characterized by: controlled release.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: February 27, 2018
    Assignee: Sidmak Laboratories (India) PVT. LTD.
    Inventors: Vinayak T. Bhalani, Anjan Kumar Paul, Ashim Kumar Sarkar
  • Patent number: 9895319
    Abstract: The invention relates to a transdermal therapeutic system (TTS), which is suited for the administration of a peptide to a patient through skin treated with ablation. The transdermal therapeutic system includes a back layer and an active substance-containing layer that contains at least one peptide and a carrier substance, preferably as a textile web material.
    Type: Grant
    Filed: December 2, 2010
    Date of Patent: February 20, 2018
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Michael Horstmann, Gerd Hoffmann, Sandra Wiedersberg
  • Patent number: 9879024
    Abstract: The present invention provides a new forms of (R)-N-methylnaltrexone, and compositions thereof, useful as a peripheral mu opioid receptor antagonist.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: January 30, 2018
    Assignees: Progenics Pharmaceuticals., Inc., Wyeth, LLC
    Inventors: Valeriya N. Smolenskaya, Kadum A. Al Shareffi, Julio Perez, Syed M. Shah, Thomas A. Boyd
  • Patent number: 9814705
    Abstract: An intranasal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: November 14, 2017
    Assignee: Depomed, Inc.
    Inventors: Peter James Watts, Jonathan David Castile, William Columbus Ian Lafferty, Alan Smith
  • Patent number: 9770442
    Abstract: The invention provides amphiphilic biocompatible copolymers which have a hydrophilic backbone and pendant hydrophobic groups. The polymers form nanoscale molecular aggregates in aqueous environments, which have hydrophobic interiors within which anticancer drugs may be solubilized. The polymers optionally feature attached antibodies, receptor ligands, and other targeting moieties which mediate adherence of the drug-carrying aggregates to targeted cancer cells.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: September 26, 2017
    Assignee: AllExcel Inc.
    Inventors: Anil Diwan, Ann Louise Onton, Jayant G. Tatake
  • Patent number: 9718821
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1, R2, R3, R4, and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: August 1, 2017
    Assignee: AbbVie Inc.
    Inventors: Keith W. Woods, Anthony Mastracchio, Chunqiu Lai, Viraj B. Gandhi, Thomas D. Penning
  • Patent number: 9717682
    Abstract: Improved pharmaceutical solid oral film dosage forms for the buccal and/or sublingual delivery of pharmaceutical, nutraceutical or cosmetic ingredients are endowed with instant hydration potential and complete dissolution potentially enabling the active ingredient to become immediately available for enhanced buccal and/or sublingual absorption and/or reduced absorption through the gastrointestinal route. The improved delivery systems for solubilizing and stabilizing pharmaceutically active ingredients exhibit enhanced stability by the use of a combination of crystallization inhibitors, which together can maintain the active ingredient in a desired plurality of particles in an effective size range within a polymeric film matrix.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: August 1, 2017
    Assignee: Intelgenx Corporation
    Inventors: Horst Zerbe, Nadine Paiement, Angela Angusti, Cormac Long
  • Patent number: 9688779
    Abstract: A troche comprising at least 5 mg hyaluronan, wherein the troche is adherent, and wherein hyaluronan is released from the troche, is used to treat mucositis, including stomatitis, vestibulitis, aphthous ulcerations, lichen planus and Behcet's syndrome. A method for treating or preventing mucositis in a patient is provided, comprising applying to a mucosal surface or a tooth or orthodontic brace of a patient in need thereof an adhering troche comprising at least 5 mg hyaluronan.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: June 27, 2017
    Assignee: OraHealth Corp.
    Inventor: Jeffrey Haley
  • Patent number: 9681936
    Abstract: A surgical implant includes at least two porous film layers each having a plurality of pores. The porous film layers are in a stacked configuration and are interconnected to one another at a plurality of attachment points to define at least one void between the porous film layers.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: June 20, 2017
    Assignee: Covidien LP
    Inventors: Gerald N. Hodgkinson, Richard P. Stevenson
  • Patent number: 9682096
    Abstract: The present invention concerns a composition comprising micro particles of polyinosinic-polycytidylic acid (Poly (I:C)) and a carrier polymer selected from starch, alginate, blanose or DPPC (dipalmitoylphosphatidylcholine) for use in preventing and/or treating viral infections of the upper respiratory tract or the common cold and a device, preferably a nasal delivery system, comprising said composition for use by a patient in need to prevent and/or treat infections or the common cold.
    Type: Grant
    Filed: May 2, 2013
    Date of Patent: June 20, 2017
    Assignee: Janssen R & D Ireland
    Inventors: Lieven Elvire Colette Baert, Bruce Albert Malcolm, Roger Paulus Maria Sutmuller
  • Patent number: 9642876
    Abstract: Provided is a method for preventing or treating sinusitis by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers. The ORP water solution can be administered alone or, e.g., in combination with one or more additional therapeutic agents.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: May 9, 2017
    Assignee: SONOMA PHARMACEUTICALS, INC.
    Inventor: Hojabr Alimi
  • Patent number: 9629392
    Abstract: A smokeless tobacco product is provided that includes a tobacco material in the form of a tobacco extract, a particulate tobacco material, or a combination thereof. In some embodiments, the smokeless tobacco product is substantially translucent. Methods for making and using the smokeless tobacco product are also provided. The smokeless tobacco product can include isomalt, maltitol syrup, particulate tobacco, and a translucent tobacco extract prepared by ultrafiltration.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: April 25, 2017
    Assignee: R.J. Reynolds Tobacco Company
    Inventor: Darrell Eugene Holton, Jr.
  • Patent number: 9629868
    Abstract: A method for treating at least one of neuro-olfactory triggered illnesses, and related conditions within a subject is provided. The method includes the steps of: a) providing a composition that includes one or more agents adapted to induce a level of anosmia/hyposmia in the subject, which level of anosmia/hyposmia is sufficient to substantially decrease olfactory sensory stimulation within the subject and a neurologic response to the stimulation that is one or both of triggering and aggravating the illness or condition; and b) applying the composition to a nasopharynx region of the subject.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: April 25, 2017
    Inventors: Joshua D. Levine, Robert A. Levine
  • Patent number: 9616060
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogs thereof, or derivatives thereof.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: April 11, 2017
    Assignee: Nektar Therapeutics
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • Patent number: 9572773
    Abstract: The layered drug delivery devices of the present invention have an outer side and an inner side. The device includes, in order from the outer side to the inner side, a first layer and a second layer. The first layer wherein the first layer is water insoluble, water swellable, and water permeable. The second layer includes a therapeutic amount of a water soluble drug and a water soluble mucoadhesive film. The second layer is disposed such that water passing through said first layer solubilizes the drug. The said solubilized drug then can permeate through a mucosal membrane when the inner side is in contact with the mucosal membrane. The drug delivery device is in sheet form.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: February 21, 2017
    Assignee: Novartis A.G.
    Inventors: Daniel Dormady, Steve Jurgens
  • Patent number: 9539248
    Abstract: This invention provides a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect. The agent for ameliorating chronic obstructive pulmonary disease contains mepenzolate bromide as an active ingredient. More preferably the mode of administration of the agent for ameliorating chronic obstructive pulmonary disease is airway administration or inhalation administration, and furthermore the mode of administration thereof is oral administration or rectal administration. This invention is a safe and effective agent for ameliorating chronic obstructive pulmonary disease (COPD) that has both a bronchodilator effect and an anti-inflammatory effect of mepenzolate bromide.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: January 10, 2017
    Assignee: LTT Bio-Pharma Co., Ltd.
    Inventors: Toru Mizushima, Hongxing Liu
  • Patent number: 9522158
    Abstract: The present invention relates to the field of viral disorders, and in particular to the use of natural compounds to inhibit viruses and viral infection. Compositions comprising NGNA are provided for treating or preventing viral infections, such as those causing the common cold.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: December 20, 2016
    Assignee: LIFE SCIENCE NUTRITION AS
    Inventors: Jan Remmereit, Dan Edwall, Anders Struksnes